Avego BioScience Capital

Activity in this selectioncape-fear-biocapital-89f4b680

By stage

Series B1

Series C+1

Undisclosed1

Biotech3

United States2

United Kingdom1

3 in this selection

May 6

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries D

Role not disclosed

Jan 27

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed

Role not disclosed

Jan 8

Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...

$107MSeries B

Role not disclosed